Sativa Wellness works toward becoming one of the best-known wellness brands

  • Sativa Wellness turns first quarterly profit
  • Sativa Wellness research could be revolutionary for CBD space

Quick facts: Sativa Wellness Group Inc


View company profile

Sativa Wellness Group Inc is a CBD wellness company.

The company manages the cultivation of raw materials, owns extraction, packaging and testing facilities, and is focused on developing consumer products under the Goodbody brand.

The product range includes CBD based gels, balms, capsules, tinctures, gummies, and other products. Geographically, it derives a majority of revenue from Europe.

12 Aug 2021

(, , , ). () has announced its first quarterly profit for the second quarter of the current year.

The firm said it has topped all targets set to diversify within the Wellness sector through the rollout of additional COVID testing clinics, with 57 clinics in operation as of Thursday.

It added it is looking at different tests to expand the clinic portfolio and opportunities to grow the testing business.

Goodbody Botanicals was listed on the UK government website to offer 2- and 8-day quarantine tests for travellers returning to the UK, offering a significant opportunity for the COVID testing clinics.

Read more

26 Jul 2021

(, , , ) has announced a new business strategy following what it said was a “strong start” to its current year.

In an announcement after Friday’s close, the company said it will align the legal entities within the group with its existing divisions of cannabidiol (CBD) products, Cannabinoid testing and Clinic Testing Services in order to achieve “clearer reporting” in 2022.

Read more

22 Jun 2021

() said it will open its fortieth clinic on Tuesday and is also expecting to get approval shortly to be part of the NHS Patient Access service.

The cannabidiol (CBD) products firm said travel restrictions are also continuing to “keep revenues flowing into the group” through its clinic network, which are currently serving a “high level of demand” for Coronavirus (COVID-19) tests from business travellers heading to countries on the UK government’s Amber travel list.

Read more

09 Jun 2021

Research from a () and King’s College London collaboration suggest that the cannabinoids CBD and CBG in combination have significant anti-inflammatory activity in the lung.

The partnership released the paper investigating the anti-inflammatory effects of two of the non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG) alone and in combination, in a model of pulmonary inflammation.

Chief executive Marc Howells is very excited about the results and is keen to develop the research further. “It could be the turning point and revolutionary for how people can see, use and reap the benefits that we believe are present in CBD.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


FTSE lacks enthusiasm for new UK economy growth figure of 4.8% as Covid…

The FTSE 100 opened lower even though the UK economy rose by 4.8% in the second quarter as businesses reopened after months of lockdown. London’s leading index slid 15 points to 7,205 in early trading.

Cineworld Group PLC (LON:CINE) expects strong trading in the coming months as people want…

56 minutes ago

3 min read


Please enter your comment!
Please enter your name here